FibroGen

San Francisco, CA, US
Year Founded: 1993

Similar Companies Hiring

Software • Healthtech • Fintech
US
340 Employees
Other • Greentech • Energy • Cloud
San Francisco, CA, US
450 Employees
Software • Social Impact • Professional Services • Healthtech • Consumer Web
San Francisco, CA, US
504 Employees
Pursuing groundbreaking science to create new standards of patient care.

FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space.


FibroGen Offices

None Workspace

Typical time on-site: None
San Francisco, CA, US